J. Keith Joung

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

J. Keith Joung is an American pathologist and molecular biologist who serves as Professor of Pathology at Harvard Medical School and the Associate Chief of Pathology at Massachusetts General Hospital.[1] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.

Education[edit]

Joung graduated at the top of his class with an A.B. in the Biochemical Sciences from Harvard College in 1987. He received his M.D. from Harvard Medical School in 1996, and his Ph.D. in Genetics from Harvard University in 1996. He completed his post-doctoral fellowship with Carl Pabo of the Massachusetts Institute of Technology and the Howard Hughes Medical Institute.

Career[edit]

Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection. Much of his research is aimed at enabling the therapeutic translation of genome editing technologies for the clinic.

In the mid-2000s, Joung's research was focused on creating zinc finger nuclease tools for biological research and gene therapy. He was the Leader and Founder of the Zinc Finger Consortium and co-authored a study on OPEN (Oligomerized Pool ENgineering), a publicly available strategy for rapidly constructing multi-finger arrays.[2][3]

More recently, Joung has contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to being the first to demonstrate the use of the CRISPR/Cas9 system in vivo through the zebrafish model,[4] Joung has pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.[5][6] In 2016, his group became one of the first to report engineered high-fidelity CRISPR-Cas9 nucleases (HF1) with no detectable off-target effects.[7]

Joung is also one of the Scientific Co-Founders of Editas Medicine, along with Jennifer Doudna, Feng Zhang, George Church, and David Liu.

References[edit]

  1. ^ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 2016-11-19.
  2. ^ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. Retrieved 2016-11-19.
  3. ^ Maeder, Morgan L.; Thibodeau-Beganny, Stacey; Osiak, Anna; Wright, David A.; Anthony, Reshma M.; Eichtinger, Magdalena; Jiang, Tao; Foley, Jonathan E.; Winfrey, Ronnie J. (2008-07-25). "Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification". Molecular Cell. 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. ISSN 1097-2765. PMC 2535758. PMID 18657511.
  4. ^ Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.
  5. ^ Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)
  6. ^ Tsai, Shengdar Q.; Nguyen, Nhu T.; Malagon-Lopez, Jose; Topkar, Ved V.; Aryee, Martin J.; Joung, J. Keith (June 2017). "CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets". Nature Methods. 14 (6): 607–614. doi:10.1038/nmeth.4278. ISSN 1548-7091.
  7. ^ Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Zheng, Zongli; Joung, J. Keith (2016-01-28). "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects". Nature. 529 (7587): 490–495. doi:10.1038/nature16526. ISSN 1476-4687. PMC 4851738. PMID 26735016.